Introduction
The Treponema pallidum haemagglutination assay (TPHA), first described by Rathlev (1965) and later modified by Tomizawa and Kasamatsu (1966) , has been used in many laboratories for the serological diagnosis of syphilis, but the function of this test and the interpretation of results have been subjects of much discussion. Garner et al. (1972) suggested that the TPHA had a similar sensitivity to the fluorescent treponemal antibody absorption (FTA-ABS) test and was therefore an acceptable alternative. Johnston (1972) stated that the sensitivity and specificity of the TPHA test compared favourably with the Treponema pallidum immobilisation (TPI) and the FTA-ABS tests. She recommended the TPHA as a simple alternative specific treponemal test that was suitable for laboratories not equipped to carry out the TPI or the FTA-ABS tests. Coffey et al. (1972) believed that a positive result to the reagin test, and a positive result to the TPHA test would indicate the presence of syphilis, and that the FTA-ABS test should be reserved for patients in whom the reagin test gave positive results and the TPHA negative sera. This opinion was not, however, shared by Blum et al. (1973) , who recorded a significant number of false positive and false negative results with the TPHA; they considered it inferior to the FTA-ABS test as a specific test for syphilis. Much of the information about the TPHA has been obtained by comparing it with the TPI or the FTA-ABS tests on selected groups of sera. A few authors (O'Neill et al., 1973; Sequeira and Eldridge, 1973) 
Materials and methods
The Wellcome TPHA was performed with microtitre equipment in accordance with the manufacturer's instructions using the recommended dilution of 1:80, and also with a starting dilution of 1:40. The Fuzizoki TPHA was tested in accordance with the manufacturer's instructions, using the micromethod.
The method used for the automated tests described by Macfarlane et al. (1976) was slightly modified. The complement titration was performed using a weak positive serum and the end point was selected to give a predetermined reading with this serum. This allowed more precise control of the sensitivity and better reproducibility of the test.
Of the samples received for testing, 80 % came from venereal disease clinics; the remaining 200% consisted of antenatal specimens and sera from hospitals and general practitioners that had been submitted for routine investigation or to comply with emigration requirements. All sera were tested in parallel using the automated tests and the TPHA. Sera which gave a positive result in any one of the tests were checked using the FTA-ABS test. The comparison was divided into three separate sections -namely, the Wellcome TPHA, the Wellcome TPHA 1:40, and the Fuzizoki TPHA. (Tables 4 and 5 ). Five of these were latent, one was congenital, and one primary. A similar situation exists in the recording of false negatives. If the TPHA is compared with a crude screening system, then few false negative results will be recorded. If selected groups are tested by the TPHA, the results will depend to a large extent on how these sera are chosen. If they contain a large number of sera from secondary, tertiary or old treated cases, few false negative results will be recorded, but if there are many sera from early cases, then the percentage of false negative results will grgatly increase. Testing selected groups of sera is not therefore strictly comparable to routine laboratory work.
Several authors have previously noted that the TPHA is not a sensitive test for primary syphilis (Table 6 ). This could not be confirmed in the present series because, of the 72 positive results, only five were from patients with primary syphilis.
Of the seven cases 'missed' by both TPHA tests (Tables 4 and 5) , five were patients with latent syphilis. O'Neill et al. (1973) found reduced TPHA titres in latent syphilis and Johnston (1972) reported a reduction in sensitivity of the TPHA in latent syphilis. It is possible that the TPHA is not a very sensitive test for latent syphilis either.
As a quantitative test for syphilis, the TPHA suffers from the disadvantage that the levels of the antibody it detects vary greatly at the same stage of infection. As the antibody persists for many years even in cases of successfully treated syphilis it is, therefore, of little value for monitoring treatment.
Judged by all these criteria, the TPHA compares unfavourably with the FTA-ABS test, and we agree with Blum et al. (1973) 
